Drug Trial Radar · NCT06682169
Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
Last checked: Nov 20, 2026Latest source record: Dec 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
182
Planned (sponsor's estimate)
Start
Nov 20, 2024
Primary completion
Oct 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
Conditions
- Graft-versus-host Disease
Interventions
RovadicitinibDrug
Rovadicitinib is an inhibitor of Janus associated kinases (JAK) family and Rho associated kinases (ROCK). It can inhibit the sustained abnormal activation of the Janus kinase (JAK) signal transducer and activator of transcription (JAK-STAT) pathway and also inhibit Rho associated kinase 2 (ROCK2). The JAK 1-JAK 2 signaling pathway is a key step in causing inflammation and tissue damage in acute and chronic graft-versus-host disease.
ImatinibDrug
Imatinib tyrosine kinase inhibitor is a small molecule protein kinase inhibitor that has the ability to block one or more protein kinases. Clinically used for the treatment of chronic myeloid leukemia and malignant gastrointestinal stromal tumors.
MethotrexateDrug
Methotrexate is an organic compound, mainly used as an anti folate anti-tumor drug. It inhibits the synthesis of tumor cells by inhibiting dihydrofolate reductase, thereby inhibiting the growth and reproduction of tumor cells.
Mycophenolate mofetilDrug
Metoprolol ester is an organic compound mainly used as an immunosuppressant
RituximabDrug
Rituximab activates antibody dependent cell-mediated phagocytosis and complement dependent cytotoxicity by binding to cluster of differentiation 20 (CD20) antigen, clearing malignant B cells expressing CD20 and achieving therapeutic goals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective remission rate in the 24th week (ORR)Time frame: Week 24
Locations
41 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of USTC Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Peking University First Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
The Southwest Hospital of AMU
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Not yet recruiting
The First Hospital of Lanzhou University
Lanzhou, Gansu, China · Not yet recruiting
The 904 Hospital of the Joint Service Support Force of the People's Liberation Army of China
Lanzhou, Gansu, China · Not yet recruiting
Guangzhou First People's Hospital The First People's Hospital Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Nanfang Hospital
Guangzhou, Guangdong, China · Not yet recruiting
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, China · Not yet recruiting
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China · Not yet recruiting
The Second Hospital of Hebei Medical Hospital
Shijiazhuang, Hebei, China · Not yet recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Not yet recruiting
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan, China · Not yet recruiting
Henan Cancer Hospital
Zhenzhou, Henan, China · Recruiting
Wuhan Union Hospital of China
Wuhan, Hubei, China · Not yet recruiting
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, China · Not yet recruiting
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China · Not yet recruiting
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Huai'an Second People's Hospital
Huai'an, Jiangsu, China · Not yet recruiting
Zhongda Hospital Southeast University
Nanjing, Jiangsu, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Not yet recruiting
First Hospital of Jilin University
Changchun, Jilin, China · Not yet recruiting
The First Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Not yet recruiting
Tai'an City Central Hospital
Tai’an, Shandong, China · Not yet recruiting
Shanghai Jiao Tong University School of Medicine,Renji Hospital
Shanghai, Shanghai Municipality, China · Not yet recruiting
Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Not yet recruiting
Shanxi Provincial People's Hospital
Xi’an, Shanxi, China · Not yet recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Not yet recruiting
Chinese Academy of Medical Sciences Hematology Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
The First Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China · Not yet recruiting
The First People's Hospital of Yunnan Province
Kunming, Yunnan, China · Not yet recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
The Affiliated People's Hospital of Ningbo University
Ningbo, Zhejiang, China · Not yet recruiting
The First Affiliated Hospital of Ningbo University
Ningbo, Zhejiang, China · Not yet recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.